Insulin resistance, a pivotal factor in the development of metabolic syndrome, is believed to play a significant role in the development of numerous types of cancer through multiple complex pathways, including hyperinsulinemia, increased bioavailability of insulin-like growth factor-1 (IGF-1), and chronic inflammation (7–10). This evidence concerns the gene IGF1 and cancer.